BRAF and neoplasm: Sufficient tumor material was available from fourteen patients treated with certolizumab (14/18; 78%) for EGFR, KRAS, BRAF, ERBB2, and ALK testing and from ten patients (10/18; 56%) for NGS (Supplementary Table 1).